Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02856113 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Alogliptin Pediatric Study
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 152
- Enrollment target
NCT02856113 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 152 participants.
The verdict
NCT02856113, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 152 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg) once daily compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the glycosylated hemoglobin (HbA1c) change from Baseline at Week 26 in pediatric participants with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG Alogliptin Benzoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2016-10-14 |
| Est. Completion | 2022-02-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02856113
The ClinicalTrials.gov registry entry for NCT02856113 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02856113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02856113 about?
NCT02856113 is a clinical study titled "Phase 3 Alogliptin Pediatric Study". The primary purpose of this study is to evaluate the efficacy of alogliptin 25 milligram (mg) once daily compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin, as measured by the glycosylated...
What is the current status of trial NCT02856113?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 152 participants. The study started on 2016-10-14. Estimated completion is 2022-02-14.
What interventions are being tested in trial NCT02856113?
The interventions under investigation include: Placebo (DRUG), Alogliptin Benzoate (DRUG).
Who is sponsoring clinical trial NCT02856113?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.